Steve Mitgang
CIK 1496250 · last filed 2019-06-10
Steve Mitgang is a corporate insider who has filed 14 SEC Form 4 insider transactions across 1 company since 2016. The most recent filing, for NTN, was dated Jun 10, 2019.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
NTN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Ernexa Therapeutics Inc. (NTN) Delisted | Director | 1,813 | $2.70 | $4.9K | $0 | 6 | 2019-06-10 |
Recent Filings
14 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-06-10 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-12 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-10-03 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | +816 | $0 | EDGAR |
| 2017-07-05 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | +697 | $0 | EDGAR |
| 2017-06-09 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-06-06 | Ernexa Therapeutics Inc. (NTN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2015-06-24 | — | Buy (P) | +15,000 | $6.3K | |
| 2015-06-19 | — | Buy (P) | +10,000 | $2.6K | |
| 2015-06-08 | — | Grant (A) | — | $0 | |
| 2015-06-03 | — | Buy (P) | +5,000 | $2.1K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.